Influenza vaccination in the pediatric emergency department setting appears to be a cost-effective strategy.
Temporary discontinuation of methotrexate after influenza vaccination is associated with improved immunogenicity of vaccination in RA.
Low education and low income are linked to lower uptakes of PCV13 in minorities 65 years and older.
Despite the loss of the live attenuated influenza vaccine, overall immunization rates in children 2-17 remained steady.
The American Academy of Pediatrics recommends against the use of the quadrivalent live attenuated influenza vaccine (LAIV4).
Fewer children were immunized against influenza once the CDC ruled out use of the nasal spray.
Hospitalization risk was increased in infants of vaccinated vs nonvaccinated mothers only during the first 90 days of life.
There is no conclusive evidence to support the use of vaccines for preventing the common cold.
Data from the 2015-2016 season shows that the live attenuated influenza vaccine was ineffective among children ages 2-17.
Influenza and pulmonary-related hospitalizations were lower in elderly patients who received the high-dose trivalent influenza vaccine vs the standard dose.
During the 2015-2016 flu season, approximately 59.3% of children and 41.7% of adults received the influenza vaccine.
Developed in Cuba, the TG4010 and CIMAvax-EGF vaccines are undergoing clinical study in the US.
Immunogenicity of 4 different vaccine strains, including H1N1, H3N2, and B influenza, were examined.
A new study found no risks for exacerbation of asthma in children given LAIV, despite ACIP recommendations against its use in children with asthma.
"It is foreseeable that in the coming weeks, challenges to our vaccination system will come from three directions at once."
The inactivated monovalent influenza A(H1N1) vacccines in both adjuvanted and unadjuvanted forms were more effective in children than adults.
Birth weight and week's gestation of infants at birth are not affected by maternal influenza vaccination during any trimester of pregnancy.
No safety signals were observed with the administration of quadrivalent live attenuated influenza vaccine, according to a large population study.
Researchers evaluated whether administering double-dose IIV4 to children younger than 3 years of age improved protection against influenza B without increasing adverse events in a phase 3 trial.
The live attenuated influenza vaccine, LAIV, is safe in children under 2 with underlying medical conditions.
Hospitalization rates for parapneumonic empyema in US children fell after introducing the 13 valent pneumococcal conjugate vaccine PCV13.